For the Inventor, By the Inventor

Enter assignee name

Taiho Pharmaceutical Company Limited

USPTO Granted Patents = 318

CIPO Patents = 16

EPO Patents = 111

Trademarks = 61

Forward Citations = 1,371

Loading Chart...

Loading Chart...

479 inventors (with patents filed for the assignee):

Makoto Kajitani (22 out of 22 patents)

Tetsuji Asao (20 out of 23 patents)

Mitsugi Yasumoto (19 out of 19 patents)

4. Kazuo Ogawa (18 out of 19 patents)

5. Motoaki Tanaka (18 out of 18 patents)

6. Masakazu Fukushima (17 out of 43 patents)

7. Setsuro Fujii (16 out of 69 patents)

8. Yuji Yamada (15 out of 17 patents)

9. Setsuo Takeda (15 out of 16 patents)

10. Takaji Honna (15 out of 15 patents)

11. Tadashi Shimamura (13 out of 17 patents)

12. Norio Unemi (13 out of 16 patents)

13. Makoto Kitade (12 out of 12 patents)

14. Hidekazu Miyake (12 out of 12 patents)

15. Shozo Yamada (11 out of 13 patents)

Core Competencies:

Phenol Compounds

Pyrazolo Compounds

Antitumor Agents

SHP2 Inhibitors

Combination Therapy

Fused Pyrimidine Compounds

EGFR Inhibitors

Pharmaceutical Compositions

Azabicyclic Compounds

Immunomodulators

Fibrosis Therapeutics

Cyclohexenone Derivatives

318 patents: Sort by Forward Citations

1. 12479834 - Phenol compound or salt thereof (2025-11-25),

2. 12458640 - Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors (2025-11-04),

3. 12435128 - Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 (2025-10-07),

4. 12419858 - Salt of terphenyl compound (2025-09-23),

5. 12414940 - Method of treating malignant tumor by azabicyclic compound (2025-09-16),

6. 12344588 - Sulfonamide compounds and use thereof (2025-07-01),

7. 12280045 - Antitumor agent and antitumor effect potentiator (2025-04-21),

8. 12258376 - Fusion protein of DCTN1 protein with RET protein (2025-03-25),

9. 12251447 - Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer (2025-03-18),

10. 12239653 - Combination decitabine and cedazuridine solid oral dosage forms (2025-03-04),

11. 12215109 - Crystal of pyrazolo[3,4-d]pyrimidine (2025-02-04),

12. 12186320 - Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient (2025-01-07),

13. 12144892 - Pharmaceutical composition (2024-11-19),

14. 12065430 - Indazole compound or salt thereof (2024-08-20),

15. 12037345 - Heterobicyclic compounds for inhibiting the activity of SHP2 (2024-07-16),

Taiho Pharmaceutical Company Limited is a leading research-based pharmaceutical company headquartered in Tokyo, Japan. Established in 1943, Taiho specializes in the discovery, development, and marketing of innovative therapies in areas such as oncology, gastroenterology, and immunology. With a strong focus on personalized medicine and patient-centric solutions, Taiho is dedicated to improving global healthcare through its high-quality pharmaceutical products and ongoing investments in research and development.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

318 Patents

#237 in Tokyo

#504 in Japan

#2,747 in the World

Taiho Pharmaceutical Company Limited

Forward Citations = 1,371

479 inventors:

Makoto Kajitani (22 out of 22 patents)

Tetsuji Asao (20 out of 23 patents)

Mitsugi Yasumoto (19 out of 19 patents)

4. Kazuo Ogawa (18 out of 19 patents)

5. Motoaki Tanaka (18 out of 18 patents)

Please report any incorrect information to support@idiyas.com

Loading…